Advancing Global Genomic Equity: The Case for National Genome Projects in Africa
核心洞察
African populations represent only 0.15% of GWAS participants and less than 2% of global genomic datasets, creating a critical data gap that limits disease research and precision medicine worldwide.
Several African nations including Tunisia, Egypt, Senegal, South Africa, Tanzania, and Kenya have launched or announced national genome projects, building on infrastructure developed during the COVID-19 pandemic.
Expanding pathogen genomic sequencing platforms to human genomics offers a sustainable pathway to address both noncommunicable diseases and pandemic preparedness across the continent.
The stark underrepresentation of African populations in global genomic databases represents one of the most pressing challenges in contemporary biomedical research. According to the GWAS Diversity Barometer, only 0.15% of genome-wide association study participants are from Africa, while individuals of African ancestry contribute less than 2% of global genomic datasets. This imbalance, researchers argue, not only limits the power of studies to identify disease-associated variants but also hinders understanding of human evolution and disease mechanisms worldwide.
"Accurate analysis of genomic data and phenotypic interpretation is vital for preventing, diagnosing, and treating hereditary diseases, enabling genetic counseling and promoting evidence-based decision making," note researchers in a comprehensive analysis published in Nature Communications. "Including Africa in genomic research is a moral imperative to prevent the widening of existing healthcare disparities. Personalized medicine must serve global needs, not the wealthy."
The Growing Momentum for National Genome Initiatives
A growing number of African nations are taking concrete steps to close this gap. Tunisia's Genome Tunisia Project aims to sequence 10,000 healthy genomes and thousands of clinical exomes to create a national reference genome resource. Egypt's Genome Egypt Project, launched in 2021, plans to sequence 100,000 healthy individuals and 200 ancient mummies to identify disease-linked variants. Senegal's SEN-GENOME Project takes a decentralized approach, sequencing 1,000 genomes from 31 ethnolinguistic groups across its 14 administrative regions.
At the African Society of Human Genetics Conference in Uganda in 2025, Tanzania, South Africa, and Kenya all announced national genome projects and presented preliminary plans. Nigeria represents a public-private partnership model, while countries including the Democratic Republic of the Congo, Ghana, Uganda, Botswana, and Gambia are leveraging existing research data to build national efforts.
"The success of the Human Heredity and Health in Africa (H3Africa (搜索)) consortium underscores the potential of Africa-led genomic research, having built local capacity and showcasing how African genetic diversity powers discoveries in human health and disease," the analysis states.
From Pandemic Response to Precision Medicine
The COVID-19 pandemic catalyzed a rapid expansion of pathogen genomic sequencing capacity across Africa. At the pandemic's onset, only 5,245 SARS-CoV-2 genomes from Africa were publicly available. By March 2022, nearly 100,000 of the 307,565 COVID genomes shared globally originated from the continent.
The Institut Pasteur de Dakar (IPD) in Senegal emerged as a leading institution in this transformation, developing a diversified sequencing ecosystem capable of matching workflows to different public health needs. IPD has since initiated a pilot program focused on whole-genome sequencing of women with early-onset breast cancer (搜索) in Senegal, building directly on pandemic-era infrastructure.
Breast cancer (搜索) kills nearly half of women diagnosed in Senegal normalized to its incidence, a much higher rate than in high-income countries, reflecting late presentation, limited diagnostic capacity, and restricted access to targeted therapies. By integrating human whole-genome sequencing into existing laboratory infrastructure, IPD's program seeks to address urgent clinical needs while generating foundational genomic data for sub-Saharan African populations.
The Clinical Imperative
The absence of large-scale African genomic data has direct clinical consequences. In testing for breast and ovarian cancer, women of African ancestry are more likely to receive "variant of uncertain significance" results because reference genomic data remains insufficient. Pharmacogenetics research has demonstrated that treatments optimized for populations of European descent yield poorer outcomes in African populations.
"A one-size-fits-all approach to medicine is ineffective and inequitable. Population genetics can help resource-limited systems provide effective treatments," the researchers emphasize.
In rare-disease diagnostics, whole-genome sequencing can increase the proportion of cases diagnosed by up to 30% in certain cohorts. In epilepsy, genetic diagnosis can directly alter therapeutic strategies by identifying medications that may provoke adverse outcomes and guiding optimal dosing.
Funding and Governance Challenges
Sustainable funding remains a central challenge. The analysis proposes integrating genomic research into national budgets by allocating a modest percentage of health or education spending. Innovative mechanisms such as health bonds, successfully used to finance public health programs globally, could be tailored to support genomic research. Botswana's model of using natural resource revenues to fund healthcare initiatives offers another potential pathway.
In 2024, Africa CDC (搜索) convened a consultative meeting to develop a continental roadmap for genomic medicine. Aligning this initiative with the African Union's Agenda 2063, which emphasizes science, innovation, and equity, is expected to help ensure sustained political commitment.
Regional collaborations through entities like the East African Community and the Southern African Development Community could foster shared genomic hubs, strengthening sequencing capacities, data analysis, training, and equitable access to genomic technologies. Countries with established infrastructure, such as South Africa, Egypt, and Tunisia, can support neighboring nations in building capacity.
Data Sovereignty and Ethical Governance
Federated data access, where analysis occurs within the country of origin, is gaining traction as a model for equity and protecting data sovereignty. This approach aligns with data protection laws and supports local oversight and autonomy, though it requires substantial investment in infrastructure, a skilled workforce, and long-term funding.
"Protecting data sovereignty and fostering public trust will be critical to ensuring equitable use of genomic data," the researchers note. "Ethical frameworks emphasizing equity and transparency will help Africa leverage genomic diversity for regional and global health."
The WHO's Technical Advisory Group on Genomics has recently launched principles for genomic data collection, access, use, and sharing, providing guidance for African nations navigating these complex governance questions. Harmonizing data laws across the continent to support responsible sharing while protecting sovereignty would accelerate research, improve healthcare, and position Africa as a key player in global genomic science.
The Human Genome Project generated 3.8 million job-years, demonstrating the potential economic impact of large-scale genomic initiatives. As the WHO Science Council and the EU-Africa Personalized Medicine project have emphasized, enhancing genomics research in Africa should be a priority to ensure the continent is not left behind in the international drive for personalized medicine and more effective healthcare systems across the globe.